

A

JC772 U.S. PTO  
08/04/00

PATENT  
ATTORNEY DOCKET NO.: 045636-5039

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC875 U.S. PTO  
09/632806  
08/04/00

Commissioner for Patents  
**BOX PATENT APPLICATION**  
Washington, D.C. 20231

**TRANSMITTAL FOR A NEWLY EXECUTED ORIGINAL APPLICATION  
UNDER 37 C.F.R. §1.53(b)**

This is a request for filing a patent application under 37 C.F.R. §1.53(b) for:

Inventors: Lise THIBODEAU and Claude LAVALLEE

For: USE OF HIV-1 gp120 AND gp160 PROTEINS MODIFIED IN THE V3 LOOP FOR  
THE PREPARATION OF VACCINE COMPOSITIONS AND FORMULATIONS  
CONTAINING THE SAME

1. This is a new ☒ **Utility** ☐ **Design** ☐ **Plant** patent application.
2. The papers enclosed to obtain a filing date are as follows:  
25 Pages of Specification including  
0 Title Page  
3 Pages of Claims  
1 Page of Abstract  
0 Sheets of drawings containing \_\_\_ Figures  
☐ The enclosed drawing(s) are photograph(s), and there is also attached a  
PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)
3. Combined Declaration and Power of Attorney  
☐ Enclosed and is executed by all inventors.  
☒ Not Enclosed.  
This application is being filed under the provisions of 37 C.F.R. §1.53(f).  
Applicant(s) await notification from the Patent and Trademark Office of the time  
set for filing the Declaration and paying the filing fees.

## 4. Language

☒ English☐ Non-English

This application is being filed in accordance with 37 C.F.R. §1.52(d) and §608.01 of the MPEP. Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the verified English translation and the processing fee.

## 5. Assignment

☐ An assignment of the invention to \_\_\_\_\_ and a PTO Form-1595, Recordation Form Cover Sheet, are enclosed.

☒ An assignment will be filed at a later date.

## 6. Priority - foreign applications under 35 U.S.C. §119(a)-(d) or §365(b) or PCT international applications under 35 U.S.C. §365(a) designating at least one country other than the U.S.

☒ Priority of the following foreign application is claimed:

Country	Application No.	Filed
France	0004310	April 4, 2000

Certified copy: ☐ is/are attached. ☒ will follow.

## 7. Priority based on provisional application(s) - 35 U.S.C. §119(e)

☐ Priority of the following provisional application(s) is claimed:

Application No.	Filed

## A. Relate Back - 35 U.S.C. §119(e)

- ☐ Amend the specification by inserting before the first line the sentence:  
 "This application claims priority of copending provisional application(s)  
 No. \_\_\_\_\_ filed on \_\_\_\_\_."

## 8. Small entity status

- ☐ A statement claiming small entity status under 37 C.F.R. §§1.9 and 1.27 is enclosed.

## 9. Fee Calculation (37 C.F.R. §1.16)

CLAIMS FOR FEE CALCULATION				
	Number Filed	Number Extra	at Rate of	Basic Fee Utility \$690.00 Design \$310.00
Total Claims (37 C.F.R. §1.16(c))	20 - 20 =		\$ 18.00 each=	\$0.00
Independent Claims (37 C.F.R. §1.16(b))	3 - 3 =		\$ 78.00 each=	\$0.00
Multiple dependent claim(s), if any (37 C.F.R. §1.16(d))			\$260.00	+
SUB-TOTAL =				\$690.00
Reduction by 1/2 for filing by a small entity				- \$
TOTAL FILING FEE =				\$690.00

## 10. Fee Payment

- ☒ Not Enclosed. **NO FEE IS BEING PAID BY CHECK OR DEPOSIT ACCOUNT AT THIS TIME.**  
 This application is being filed under the provisions of 37 C.F.R. §1.53(f).  
 Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the Declaration and paying the filing fees.

☐ Enclosed.

Two checks in the amounts of \$\_\_\_\_\_ and \$40.00 representing the basic filing fee of \$690.00 and an assignment recording fee of \$40.00 is/are enclosed.

11. ☒ **Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).


12. Additional papers enclosed:

- ☒ Preliminary Amendment  
☐ Information Disclosure Statement  
☐ Form PTO-1449, \_\_\_\_\_ documents included  
☐ Declaration of Biological Deposit  
☐ Submission of "Sequence Listing", computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.

**Please accord this application an application number and filing date.**

Respectfully submitted,

**MORGAN, LEWIS & BOCKIUS LLP**



Elizabeth C. Weimar

Reg. No. 44,478

Dated: August 4, 2000

**Customer No. 009629**

**MORGAN, LEWIS & BOCKIUS LLP**

1800 M Street, N.W.

Washington, D.C. 20036

(202) 467-7000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Lise THIBODEAU *et al.* )  
)  
Application No.: ) Group Art Unit: Unassigned  
)  
Filed: August 4, 2000 ) Examiner: Unassigned  
)  
For: USE OF HIV-1 GP120 AND GP160 )  
PROTEINS MODIFIED IN THE V3 )  
LOOP FOR THE PREPARATION OF )  
VACCINE COMPOSITIONS AND )  
FORMULATIONS CONTAINING )  
THE SAME )

Commissioner for Patents  
Washington, D.C. 20231

Sir:

**PRELIMINARY AMENDMENT**

Prior to the examination on the merits, please amend this application as follows.

**IN THE SPECIFICATION**

In the specification, pages 10-24 are mis-numbered, please amend the numbers of these pages to be 9-23, respectively

**IN THE CLAIMS:**

Please cancel claims 1-5.

Please amend claims 6-12 as follows:

Claim 6, line 1, change "Pharmaceutical" to --A pharmaceutical--;

lines 2 and 3, change "characterized in that it essentially consists of" to --  
consisting essentially of--;

line 5, change "either Claim 3 or Claim 4" to Claim 15;

Claim 7, lines 1 and 2, change "Formulation according to Claim 6, characterized in that"  
to --The formulation according to Claim 6, wherein--;

Claim 8, lines 1 and 2, change "Formulation according to Claim 7, characterized in that"  
to --The formulation according to Claim 6, wherein--

Claim 9, lines 1 and 2, change "Formulation according to any one of Claims 6 to 9,  
characterized in that" to --The formulation according to Claim 6, wherein--;

Claim 10, lines 1 and 2, change "Formulation according to any one of Claims 6 to 9,  
characterized in that it comprises to --The formulation according to Claim 6 comprising--;

line 7, after "derivative" insert --- and delete the remainder of the sentence;

Claim 11, line 1, change "Pharmaceutical" to --A pharmaceutical--;

lines 2 and 3, change "characterized in that it essentially consists of" to --  
consisting essentially of--;

line 3, change "either Claim 3 or Claim 4" to --Claim 15--;

Claim 12, line 1, change "Formulation" to --The formulation--;

line 2, change "characterized in that" to --wherein--;

Please add new claims as follows:

--13. A method of inhibiting HIV-1 infection comprising administering a recombinant HIV-1 envelope protein in which the V3 loop is partially or completely deleted, in an amount effective for inducing a humoral, cellular and mucosal immune response.

14. The method of claim 13 wherein the envelope protein is selected from the group consisting of the recombinant gp160 and gp120 Env proteins in which the V3 loop is partially deleted, and the recombinant gp160 and gp120 Env proteins in which the V3 loop is completely deleted.

15. A vaccine comprising a recombinant envelope protein according to claim 13 and at least one pharmaceutically acceptable vehicle.

16. The vaccine of claim 15 further comprising at least one compound selected from the group consisting of :

(1) the vaccination adjuvants selected from the group consisting of derivatives comprising divalent or trivalent ions: aluminum hydroxide or calcium phosphate, and muramylpeptide derivatives and

(2) liposomes.

17. The vaccine of claim 15 wherein the envelope protein is anchored onto unilamellar synthetic lipid vesicles.

18. The vaccine of claim 17 wherein the vesicles comprise a molar ratio of phosphatidylcholine to cholesterol of about 8:1, and which have a size of between 70 and 150 nm.

19. The vaccine of claim 18 wherein the size of the vesicles is about 90 nm.

20. The vaccine of claim 15 formulated either for oral administration or general administration.--

**REMARKS**

The changes to the claims requested above are to eliminate multiple claim dependency and to present claim language more conventional for practice in the United States. These changes do not introduce new matter nor do they alter the subject matter presented.

**CONCLUSIONS**

If there are any other filing or claim fees due in connection with the filing of this preliminary amendment, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for any extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account. The Examiner is invited to telephone the undersigned at his convenience.

Respectfully submitted,

**MORGAN, LEWIS & BOCKIUS LLP**

Date: **August 4, 2000**

By: Elizabeth C. Weimar  
Elizabeth C. Weimar  
Reg. 44,478

MORGAN, LEWIS & BOCKIUS LLP  
1800 M Street, NW  
Washington, DC 20036  
(202) 467-7000



The present invention relates to the use of HIV-1 gp120 and gp160 proteins which have been modified in the V3 loop for preparing vaccine compositions, as well as to formulations containing them which are capable of producing a humoral, cellular and mucosal immune response.

The type-1 human immunodeficiency virus (HIV-1) is the aetiological agent of AIDS. HIV-1 induces a persistent infection in humans which leads to a severe immunodeficiency. The envelope of HIV is composed of two glycoproteins, gp120 and gp41, which are derived from a precursor, gp160, by proteolytic cleavage. Five conserved regions, C1 to C5, and five variable regions, V1 to V5, have been demonstrated in the glycoprotein of the envelope. Three functional regions play an essential role in the first steps of the infection, and have been identified: the CD4-binding site (in the C4 region), the V3 region, which is essential to infectivity, and finally a very hydrophobic region which is located at the N-terminal end of gp41, and which participates in the fusion between the membrane of the target cell and the viral envelope. The V3 loop is hypervariable, immunodominant and corresponds to the principal neutralizing-antibody-inducing determinant (PND).

It is generally accepted that neutralizing antibodies play an important role in protection against viral infection (1, 2).

However, in the case of the type 1 human immunodeficiency virus (HIV-1), the neutralizing antibodies which develop at an early stage of the infection do not prevent the progression of the disease.

Specifically, in infected individuals, the neutralizing antibodies, when they exist, exhibit a very narrow neutralization range and often do not neutralize the strain(s) which infect(s) the patient (3, 4). In the same way, the neutralizing antibodies induced by vaccination with gp160/120 in solution are

generally specific for the strain used for the vaccine preparation and are directed against one or more determinants in the V3 loop of gp120 (5).

Although the V3 loop is hypervariable, a Gly-Pro-Gly-Arg (GPGR) tetrapeptide which is located at the top of the loop, as well as two cysteines at its base, are present in almost all known isolates of HIV-1, which indicates that this sequence is essential to a vital cycle step of the virus (6).

The roles of the V3 loop (cellular tropism, infectivity, induction of restricted-range neutralizing antibodies and role in pathogenesis) have been demonstrated (6).

The inventors have modified the env gene of HIV-1 by carrying out deletions which eliminate or decrease the hypervariable epitopes of the V3 loop. The results, obtained with a partial deletion in the V3 loop of gp160 while keeping the tip of the V3 loop, i.e. the GPGRAPH sequence and the two cysteines at its base, show that the modified protein  $\Delta V3$ -GPGRAPH is expressed in the same way as the unmodified protein, and that it reacts with an anti-HIV human reference serum to a degree which is similar to unmodified recombinant gp160 (7).

A protein in which the V3 loop is completely deleted was also produced; it is the protein  $\Delta V3+$ , which is also expressed and which has a molecular mass compatible with the deletion.

This set of elements has led the inventors to formulate the hypothesis that the V3 loop would represent a decoy for the immune system, and that the modification or elimination of this loop might induce a conformational change in the molecule, which would reveal itself by the induction of a neutralizing activity directed against other epitopes which are more conserved but which show weak immunogenicity during the natural infection or subsequent to a vaccination with the native protein.

Faced with the AIDS epidemic, the development of an anti-AIDS vaccine which is capable of halting the propagation of the disease is imperative; indeed, the World Health Organization estimates that in 2002, there  
5 could be between 50 and 75 million people in the world infected with HIV.

The inventors consequently gave themselves the goal of producing a vaccine composition which is better at meeting the requirements of the art in that it is  
10 capable of inducing a humoral, cellular and mucosal immune response which exhibits a wide-ranging neutralization due to the induction of antibodies which are capable of neutralizing various types of HIV-1 strain, and in particular both laboratory strains and  
15 clinical strains (primary isolates).

A subject of the present invention is the use of a recombinant HIV-1 Env protein, in which the V3 loop is partially or completely deleted, for preparing a vaccine composition which is capable of inducing an  
20 immunity which is at the same time humoral, cellular and mucosal with respect to divergent strains of HIV-1.

The inventors have now found, surprisingly, that the proteins in which the V3 loop is partially or completely deleted are actually capable of inducing a  
25 wide-ranging protective immunity which is at the same time humoral (neutralizing antibodies), cellular (cytotoxic T lymphocytes) and mucosal (neutralizing secretory IgA productions).

"Wide-ranging immune response or immunity" is  
30 intended to mean the set of humoral and cellular factors which protects the body against an HIV-1 infection, in accordance with the definition by J.F. Bach (Immunology Treaty, Flammarion, 1993).

In accordance with said use, said recombinant  
35 Env protein is selected from the group consisting of the Env proteins in which the V3 loop is partially deleted:  $\Delta$ V3-GPGRAPH recombinant gp160 and gp120 proteins, and the Env proteins in which the V3 loop is

004080" 90322950

completely deleted:  $\Delta V3+$  recombinant gp160 and gp120 Env proteins.

A subject of the present invention is also a vaccine composition, characterized in that it  
5 comprises:

- a recombinant Env protein as defined above,
- optionally at least one compound selected from the group consisting of:

(1) the vaccination adjuvants selected from the  
10 group consisting of derivatives comprising divalent or trivalent ions: aluminium hydroxide or calcium phosphate, and muramylpeptide derivatives and

(2) liposomes and  
- optionally at least one pharmaceutically  
15 acceptable vehicle.

According to one advantageous embodiment of said vaccine composition, it comprises a recombinant Env protein as defined above which is anchored onto unilamellar synthetic lipid vesicles or liposomes  
20 (immunosomes) which comprise a phosphatidylcholine:cholesterol molar ratio of about 8:1, and which have a size of between 70 and 150 nm, preferably 90 nm, as described in patent EP 47480.

Such a vaccine composition can advantageously  
25 be administered either generally or systemically: orally, parenterally, or locally (via the rectal or vaginal route, for example); it is preferably administered via a route which involves a direct contact with a mucous membrane, and which thus makes it  
30 possible to obtain a stimulation of the mucosal immune response.

The vaccine composition according to the invention can advantageously be provided in various pharmaceutical formulations which are particularly well  
35 suited to the route of administration and to the desired effect, i.e. obtaining a humoral, cellular and/or mucosal immune response.

A subject of the present invention is thus also a pharmaceutical formulation intended for oral

004020" 50226 250

administration, characterized in that it essentially consists of:

- a core consisting of a vaccine composition as defined above embedded in a gelatin and

5           - a coating selected from the group consisting of a film-forming polymer which is soluble or expandable in water and soluble in solvents and which is selected from the group consisting of cellulose derivatives, polyvinylpyrrolidone, acrylic and  
10 methacrylic esters, polyethylene glycols, polyvinyl alcohols, vinylpyrrolidone/vinyl acetate copolymer, vinylpyrrolidone/polyvinyl alcohol copolymer and protein substances such as zein or gliadin.

          Preferably, said film-forming agent is selected  
15 from the group consisting of cellulose ethers and esters, such as cellulose acetate, cellulose acetate phthalate, cellulose butyrate, ethylcellulose and methylcellulose.

          According to one advantageous embodiment of  
20 said formulation, said film-forming polymer is combined with at least one plasticizer chosen from glycerol and esters thereof, high molecular weight polyethyleneglycols, ricin oil and citric, phthalic, adipic and sebacic acid esters.

25           Such a formulation, which is intended for oral administration, protects the recombinant Env protein (antigen) from degradation by gastric proteases and from the acid pH of the stomach. The coating dissolves in the alkaline pH of the intestine, which releases the  
30 antigen in the vicinity of Peyer's patches, which are the major sites of induction of mucosal immunity.

          According to another advantageous embodiment of said formulation, said vaccine composition consists of a freeze-dried mixture of immunosomes, onto which a  
35 gp120/160 protein is anchored, with trehalose.

          A preferred formulation intended to be administered orally comprises:

- a core consisting of a freeze-dried mixture of immunosomes onto which a gp120/160 protein is anchored and of trehalose, embedded in gelatin and

- a coating consisting of a cellulose derivative, preferably cellulose acetate phthalate.

A subject of the present invention is thus also a pharmaceutical formulation intended for local administration to a mucous membrane (vaginal or rectal), characterized in that it essentially consists of a vaccine composition, as defined, above embedded in glycerol or a glycerol/glycerine-based mixture.

According to one advantageous embodiment of said formulation, said vaccine composition consists of a freeze-dried mixture of immunosomes, onto which a gp120/160 protein is anchored, with trehalose.

Besides the above arrangements, the invention comprises yet other arrangements which will emerge from the description which follows, which refers to examples of implementation of the method which is the subject of the present invention.

It should be clearly understood, however, that these examples are given only by way of illustration of the subject of the invention, of which they in no way constitute a limitation.

#### **Example 1: Preparation of the EnvΔV3-GPGRAPH recombinant protein**

##### **Partial deletion of the V3 loop**

The env gene of HIV-1<sub>LAI</sub> is cloned into a baculoviral system; the variable sequences of the V3 loop were eliminated by introducing a modification into the env gene of pNL4-3, conserving only the nucleotides encoding the GPGRAPH hexapeptide and the two cysteines at the base of the loop.

This modification of the V3 loop was carried out with the aid of 4 oligonucleotides. They were hybridized so as to reconstitute the modified V3 loop and cloned directly between the AseI and NheI restriction sites of an intermediate vector comprising the first 1035 nucleotides of the env gene, in such a

way as to conserve only the GPGRAPH motif and the two cysteines of the V3 region.

The modification introduced into the gene was confirmed by sequencing the V3 region, and cloned into the previously constructed transfer vector pBacPAK env (7) in order to obtain the transfer vector pBacPAK envΔV3-GPGRAPH. The latter made it possible to generate the envΔV3-GPGRAPH recombinant baculovirus (7).

#### **Expression of the recombinant env gene**

Sf21 insect cells were infected with the *Autographa californica* nuclear polyhedrosis virus (AcNPV), as well as with the envΔV3-GPGRAPH recombinant baculovirus. Three to four days post-infection, the cells were harvested, lysed in the presence of detergent and analysed by electrophoresis on 10% polyacrylamide gel, as well as by Western blot. The results showed that the cells infected with the envΔV3-GPGRAPH recombinant baculovirus express a protein which has a molecular mass compatible with deletion. This protein is recognized by a human reference serum which is positive for the HIV-1 antigens (7).

#### **Purification of ΔV3-GPGRAPH recombinant gp160**

EnvΔV3-GPGRAPH recombinant gp160 was purified by chromatography on a DEAE-cellulose column, followed by a purification on a *Lens culinaris* lectin column, from  $2 \times 10^9$  Sf21 cells infected with the envΔV3-GPGRAPH recombinant baculovirus. Analysis by electrophoresis showed that the protein was more than 80% pure.

**Example 2: Preparation of a pharmaceutical formulation according to the invention.**

#### **a. Preparation of immunosomes with ΔV3-GPGRAPH recombinant gp160**

The immunosomes were prepared by anchoring ΔV3-GPGRAPH recombinant gp160 onto preformed liposomes in accordance with the method described in patent EP 47 480. The ΔV3-GPGRAPH-immunosomes are particles of approximately 90 nm which are covered with ΔV3-GPGRAPH-gp160.

**b. Formulations of the composition obtained in**

**a.**

For the oral immunizations, the ΔV3-GPGRAPH-immunosomes are freeze-dried in the presence of  
5 threalose, and the antigen is introduced into a gelatin capsule. The capsule is coated with a mixture containing cellulose acetate phthalate, which protects the antigen from degradation by gastric proteases and from the acid pH of the stomach. The coating dissolves  
10 in the alkaline pH of the intestine, which releases the antigen in the vicinity of Peyer's patches, which are the major sites of induction of mucosal immunity.

For the immunizations via the vaginal or rectal route, the antigen is formulated in a  
15 glycerol/glycerine-based mixture which is solid at room temperature but which melts at physiological body temperature, thus gradually releasing the antigen.

**Example 3: Demonstration of the immunogenic and vaccine activity of a formulation according to Example 2.**

**20 Protocol for immunization of C57/BL mice**

In this hyperimmunization protocol, 12 mice received four injections of immunosomes containing 25 µg of ΔV3-GPGRAPH-gp160 intraperitoneally at 3-week intervals, followed by an intravenous booster. No  
25 adjuvant was used. Six control mice were subjected to the same protocol using PBS.

**Evaluation by ELISA of the immune response against the LAI, IIIB, MN and RF strains**

Two weeks after the intravenous booster, the  
30 mice were bled by intracardiac puncture, and the sera were evaluated for the presence of IgM, IgG and IgA antibodies which react with the LAI, IIIB, MN and RF strains.

All the mice developed very high titres of IgG-type antibodies against each of the four strains  
35 tested, which were between 1/65 536 and 1/524 288. Tables I, II, III and IV show that the mice also developed antibodies of the three isotypes against four laboratory strains tested.

004030" 903225 950



TABLE I

Humoral immune response of mice immunized with an immunosome-anchored  $\Delta$ V3-GPGRAPH-gp160 composition

Mouse	Immunizations	Antigen	Titre by ELISA of antibodies directed against the LAI strain		
			IgM	IgG	IgA
1	SIX	IMS- $\Delta$ V3-GPGRAPH (25 $\mu$ g)	1/2 048	1/262 144	1/256
2	idem	idem	1/1 024	1/262 144	1/256
3	idem	idem	1/2 048	1/524 288	1/512
4	idem	idem	1/512	1/131 072	1/256
5	idem	idem	1/1 024	1/131 072	1/128
6	idem	idem	1/2 048	1/262 144	1/256
7	idem	idem	1/1 024	1/262 144	1/256
8	idem	idem	1/1 024	1/65 538	1/128
9	idem	idem	1/4 096	1/524 288	1/1 024
10	idem	idem	1/4 096	1/524 288	1/1 024
11	idem	idem	1/2 048	1/262 144	1/256
12	idem	idem	1/2 048	1/262 144	1/256
13	SIX	PBS	<1/32	<1/32	<1/32
14	idem	idem	<1/32	<1/32	<1/32
15	idem	idem	<1/32	<1/32	<1/32
16	idem	idem	<1/32	<1/32	<1/32
17	idem	idem	<1/32	<1/32	<1/32
18	idem	idem	<1/32	<1/32	<1/32

TABLE II

Humoral immune response of mice immunized with an immunosome-anchored ΔV3-GPGRAPH-gp160 composition

Mouse	Immunizations	Antigen	Titre by ELISA of antibodies directed against the IIIB strain		
			IgM	IgG	IgA
1	SIX	TMS-ΔV3-GPGRAPH (25 µg)	1/2 048	1/262 144	1/256
2	idem	idem	1/1 024	1/262 144	1/256
3	idem	idem	1/2 048	1/262 144	1/512
4	idem	idem	1/1 024	1/131 072	1/256
5	idem	idem	1/1 024	1/131 072	1/128
6	idem	idem	1/2 048	1/131 072	1/256
7	idem	idem	1/1 024	1/262 144	1/256
8	idem	idem	1/1 024	1/65 536	1/128
9	idem	idem	1/4 096	1/131 072	1/1 024
10	idem	idem	1/4 096	1/131 072	1/1 024
11	idem	idem	1/2 048	1/262 144	1/256
12	idem	idem	1/2 048	1/131 072	1/256
13	SIX	PBS	<1/32	<1/32	<1/32
14	idem	idem	<1/32	<1/32	<1/32
15	idem	idem	<1/32	<1/32	<1/32
16	idem	idem	<1/32	<1/32	<1/32
17	idem	idem	<1/32	<1/32	<1/32
18	idem	idem	<1/32	<1/32	<1/32

TABLE III

Humoral immune response of mice immunized with an immunosome-anchored  $\Delta$ V3-GPGRAPH-gp160 composition

Mouse	Immunizations	Antigen	Titre by ELISA of antibodies directed against the MN strain		
			IgM	IgG	IgA
1	SIX	IMS- $\Delta$ V3-GPGRAPH (25 $\mu$ g)	1/2 048	1/131 072	1/256
2	idem	idem	1/1 024	1/131 072	1/256
3	idem	idem	1/2 048	1/131 072	1/512
4	idem	idem	1/1 024	1/65 536	1/256
5	idem	idem	1/1 024	1/65 536	1/128
6	idem	idem	1/2 048	1/65 536	1/256
7	idem	idem	1/1 024	1/131 072	1/256
8	idem	idem	1/1 024	1/65 536	1/128
9	idem	idem	1/4 096	1/131 072	1/1 024
10	idem	idem	1/4 096	1/131 072	1/1 024
11	idem	idem	1/2 048	1/262 144	1/256
12	idem	idem	1/2 048	1/131 072	1/256
13	SIX	PBS	<1/32	<1/32	<1/32
14	idem	idem	<1/32	<1/32	<1/32
15	idem	idem	<1/32	<1/32	<1/32
16	idem	idem	<1/32	<1/32	<1/32
17	idem	idem	<1/32	<1/32	<1/32
18	idem	idem	<1/32	<1/32	<1/32

TABLE IV

Humoral immune response of mice immunized with an immunosome-anchored  $\Delta$ V3-GPGRAF-gp160 composition

Mouse	Immunizations	Antigen	Titre by ELISA of antibodies directed against the RF strain		
			IgM	IgG	IgA
1	SIX	IMS- $\Delta$ V3-GPGRAF (25 $\mu$ g)	1/1 024	1/131 072	1/128
2	idem	idem	1/1 024	1/131 072	1/128
3	idem	idem	1/2 048	1/131 072	1/256
4	idem	idem	1/1 024	1/65 536	1/128
5	idem	idem	1/1 024	1/65 536	1/64
6	idem	idem	1/2 048	1/65 536	1/126
7	idem	idem	1/1 024	1/131 072	1/126
8	idem	idem	1/1 024	1/65 536	1/64
9	idem	idem	1/1 024	1/131 072	1/256
10	idem	idem	1/2 048	1/131 072	1/256
11	idem	idem	1/2 048	1/262 144	1/128
12	idem	idem	1/1 024	1/131 072	1/128
13	SIX	PBS	<1/32	<1/32	<1/32
14	idem	idem	<1/32	<1/32	<1/32
15	idem	idem	<1/32	<1/32	<1/32
16	idem	idem	<1/32	<1/32	<1/32
17	idem	idem	<1/32	<1/32	<1/32
18	idem	idem	<1/32	<1/32	<1/32

Determination of the presence of antibodies which are capable of neutralizing the infectivity of different laboratory strains

5       The sera of mice immunized with the  $\Delta$ V3-GPGRAF-gp160 immunosome were then evaluated for their potential for neutralizing the infectivity of the LAI, IIIB, MN, RF, LAV 43.01 and BAL strains. The neutralization assays are carried out using CEM cells. All the mice developed neutralizing antibodies ranging  
10   from 1/1024 to 1/126, as illustrated in Tables V and VI.

004030" 5082E360

TABLE V

Titre of neutralizing antibodies directed against divergent strains of HIV-1 in mice immunized with the immunosome-anchored  $\Delta$ V3-GPGRAPH-gp160 vaccine composition

Mouse	Immunizations	Antigen	Titre of antibodies which neutralize against 100 TCID <sub>50</sub> of:		
			LAI	IIIB	RF
1	SIX	IMS- $\Delta$ V3-GPGRAPH (25 $\mu$ g)	1/256	1/256	1/256
2	idem	idem	1/256	1/256	1/256
3	idem	idem	1/512	1/256	1/512
4	idem	idem	1/256	1/128	1/256
5	idem	idem	1/256	1/256	1/128
6	idem	idem	1/256	1/126	1/256
7	idem	idem	1/1 024	1/256	1/256
8	idem	idem	1/64	1/32	1/128
9	idem	idem	1/256	1/256	1/1 024
10	idem	idem	1/256	1/126	1/1 024
11	idem	idem	1/512	1/512	1/256
12	idem	idem	1/256	1/126	1/256
13	SIX	PBS	<1/32	<1/32	<1/32
14	idem	idem	<1/32	<1/32	<1/32
15	idem	idem	<1/32	<1/32	<1/32
16	idem	idem	<1/32	<1/32	<1/32
17	idem	idem	<1/32	<1/32	<1/32
18	idem	idem	<1/32	<1/32	<1/32

TABLE VI

Titre of neutralizing antibodies directed against divergent strains of HIV-1 in mice immunized with the immunosome-anchored  $\Delta$ V3-GPGRAPH-gp160 vaccine composition

Mouse	Immunizations	Antigen	Titre of antibodies which neutralize against 100 TCID <sub>50</sub> of:			
			LAV 43.01	MN	BAL	
1	SIX	IMS- $\Delta$ V3-GPGRAPH (25 $\mu$ g)	1/256	1/126	1/126	
2	idem	idem	1/256	1/126	1/64	
3	idem	idem	1/1 024	1/256	1/256	
4	idem	idem	1/256	1/128	1/126	
5	idem	idem	1/256	1/256	1/128	
6	idem	idem	1/256	1/126	1/256	
7	idem	idem	1/1 024	1/256	1/256	
8	idem	idem	1/32	1/32	1/64	
9	idem	idem	1/256	1/256	1/256	
10	idem	idem	1/256	1/126	1/126	
11	idem	idem	1/1 024	1/512	1/256	
12	idem	idem	1/256	1/126	1/126	
13	SIX	PBS	<1/32	<1/32	<1/32	
14	idem	idem	<1/32	<1/32	<1/32	
15	idem	idem	<1/32	<1/32	<1/32	
16	idem	idem	<1/32	<1/32	<1/32	
17	idem	idem	<1/32	<1/32	<1/32	
18	idem	idem	<1/32	<1/32	<1/32	

**Evaluation of the neutralizing power of the sera against six primary isolates**

Finally, the neutralizing power of the mouse sera was determined against six primary isolates: 5 03908, 65869, 65965, 65870, 65871 and 3929, generated from coculture of lymphocytes from patients at various stages of the disease, with lymphocytes from seronegative donors. The neutralization assays were carried out using non-stimulated PBLs. All the mice 10 developed antibodies which were capable of neutralizing the infectivity of primary isolates. By way of example, see Tables VII and VIII. The titres were generally very high, these titres being between 1/512 and 1/256 against five of the six primary isolates tested. 15 Isolate 65869 proved to be more resistant to neutralization. The titres were 1/64 and 1/32 and <1/32 in four of the sera. This isolate came from a patient in the terminal phase of the disease, and the virus induced gigantic syncytia in the cell cultures.

004030" 9022E 950



TABLE VII

Titre of neutralizing antibodies directed against divergent strains of HIV-1 in mice immunized with the immunosome-anchored  $\Delta$ V3-GPGRAPH-gp160 vaccine composition

Mouse	Immunizations	Antigen	Titre of antibodies which neutralize against 100 TCID <sub>50</sub> of:		
			# 03908	# 65869	# 65965
1	SIX	IMS- $\Delta$ V3-GPGRAPH (25 $\mu$ g)	1/126	<1/32	1/64
2	idem	idem	1/64	1/32	1/126
3	idem	idem	1/256	1/32	1/126
4	idem	idem	1/126	<1/32	1/256
5	idem	idem	1/256	1/64	1/126
6	idem	idem	1/512	1/32	1/512
7	idem	idem	1/256	1/64	1/256
8	idem	idem	<1/32	<1/32	<1/32
9	idem	idem	1/512	<1/32	1/256
10	idem	idem	1/256	1/32	1/126
11	idem	idem	1/512	1/32	1/256
12	idem	idem	1/256	1/32	1/126
13	SIX	PBS	<1/32	<1/32	<1/32
14	idem	idem	<1/32	<1/32	<1/32
15	idem	idem	<1/32	<1/32	<1/32
16	idem	idem	<1/32	<1/32	<1/32
17	idem	idem	<1/32	<1/32	<1/32
18	idem	idem	<1/32	<1/32	<1/32

TABLE VIII

Titre of neutralizing antibodies directed against divergent strains of HIV-1 in mice immunized with the immunosome-anchored  $\Delta$ V3-GPGRAPH-gp160 vaccine composition

Mouse	Immunizations	Antigen	Titre of antibodies which neutralize against 100 TCID <sub>50</sub> of:		
			# 65870	# 65871	# 3929
1	SIX	IMS- $\Delta$ V3-GPGRAPH (25 $\mu$ g)	1/64	1/126	1/64
2	idem		1/126	1/126	1/126
3	idem		1/126	1/256	1/256
4	idem		1/256	1/128	1/126
5	idem		1/256	1/126	1/126
6	idem		1/256	1/64	1/256
7	idem		1/126	1/256	1/256
8	idem		<1/32	<1/32	<1/32
9	idem		1/256	1/256	1/256
10	idem		1/256	1/126	1/126
11	idem		1/512	1/512	1/256
12	idem		1/256	1/126	1/126
13	SIX	PBS	<1/32	<1/32	<1/32
14	idem	idem	<1/32	<1/32	<1/32
15	idem	idem	<1/32	<1/32	<1/32
16	idem	idem	<1/32	<1/32	<1/32
17	idem	idem	<1/32	<1/32	<1/32
18	idem	idem	<1/32	<1/32	<1/32

These results show that partially deleting the V3 loop while keeping the conserved sequence GPGRAF promotes the induction of wide-ranging antibodies which are capable of neutralizing various laboratory strains, but also various primary isolates.

Similar results are obtained with the protein which contains a total deletion of the V3 loop.

#### REFERENCES

- 10 (1) Emini E., Schleif W., Numberg, J. et al. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-30.
- 15 (2) Girard M.P., Kieny M., Pinter A., et al. 1991. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Nat. Acad. Sci. USA 88:542-46.
- 20 (3) Nara P.L., Garrity R.R., Goudsmit J. et al. 1991. Neutralization of HIV-1: a paradox of humoral proportion. FASEB J. 5:2437-55.
- 25 (4) Palker T.J., Claar M.E., Langlois A.J et al. 1988. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-coded peptides. Proc. Nat. Acad. Sci. USA 85:1932-6.
- 30 (5) Javaherian K., Langlois J., McDonald C. et al. 1989. Principal neutralization domain of the human immunodeficiency virus type 1 envelope protein. Proc. Nat. Acad. Sci. USA 86:6768-72.
- 35 (6) Lucinda A., Dubay J.W., Morris J.F. et al. 1992. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology 187:423-32.

004080" 9082E960

- (7) Lavallée Claude and Lise Thibiodeau (1996)  
Clonage, expression et caractérisation de gp160 du  
VIH-1, portant des délétions partielles ou totales  
dans la boucle V3. [Cloning, expression and  
5 characterization of HIV-1 gp160, bearing partial  
or total deletions in the V3 loop] 1996 C.R. Acad.  
Sci. Paris 319:983-990.

As emerges from the above, the invention is in no way limited to those of its modes of implementation, execution and application which have just been described more explicitly; on the contrary, it embraces all the variants thereof which may occur to persons skilled in the art, without departing from the context or the scope of the present invention.

CLAIMS

1. Use of a recombinant HIV-1 Env protein, in which the V3 loop is partially or completely deleted,  
5 for preparing a vaccine composition which is capable of inducing an immunity which is at the same time humoral, cellular and mucosal with respect to HIV-1.
2. Use of a protein according to Claim 1, characterized in that it is selected from the group  
10 consisting of the recombinant gp160 and gp120 Env proteins in which the V3 loop is partially deleted and the recombinant gp160 and gp120 Env proteins in which the V3 loop is completely deleted.
3. Vaccine composition, characterized in that it  
15 comprises:
- a recombinant Env protein according to either Claim 1 or Claim 2,
  - optionally at least one compound selected from the group consisting of:  
20 (1) the vaccination adjuvants selected from the group consisting of derivatives comprising divalent or trivalent ions: aluminium hydroxide or calcium phosphate, and muramylpeptide derivatives and  
(2) liposomes and  
25 - optionally at least one pharmaceutically acceptable vehicle.
4. Composition according to Claim 3, characterized in that it comprises a recombinant Env protein according to either Claim 1 or Claim 2 which is  
30 anchored onto unilamellar synthetic lipid vesicles or which comprise a phosphatidylcholine:cholesterol molar ratio of about 8:1, and which have a size of between 70 and 150 nm, preferably 90 nm.
5. Composition according to either Claim 3 or  
35 Claim 4, characterized in that it can advantageously be administered generally or locally.
6. Pharmaceutical formulation intended for oral administration, characterized in that it essentially consists of:

004000" 002200 004000

- a core consisting of a vaccine composition according to either Claim 3 or Claim 4 embedded in a gelatin and

5       - a coating selected from the group consisting  
of a film-forming polymer which is soluble or  
expandable in water and soluble in solvents and which  
is selected from the group consisting of cellulose  
derivatives, polyvinylpyrrolidone, acrylic and  
methacrylic esters, polyethylene glycols, polyvinyl  
10 alcohols, vinylpyrrolidone/vinyl acetate copolymer,  
vinylpyrrolidone/polyvinyl alcohol copolymer and  
protein substances such as zein or gliadin.

7.       Formulation according to Claim 6, characterized  
in that said film-forming agent is selected from the  
15 group consisting of cellulose ethers and esters, such  
as cellulose acetate, cellulose acetate phthalate,  
cellulose butyrate, ethylcellulose and methylcellulose.

8.       Formulation according to Claim 7, characterized  
in that said film-forming polymer is combined with at  
20 least one plasticizer chosen from glycerol and esters  
thereof, high molecular weight polyethyleneglycols,  
ricin oil and citric, phthalic, adipic and sebacic acid  
esters.

9.       Formulation according to any one of Claims 6 to  
25 8, characterized in that the vaccine composition  
consists of a freeze-dried mixture of immunosomes onto  
which a gp120/160 protein is anchored and of trehalose.

10.       Formulation according to any one of Claims 6 to  
9, characterized in that it comprises

30       - a core consisting of a freeze-dried mixture  
of immunosomes, onto which a gp120/160 protein is  
anchored, with trehalose, embedded in gelatin and

      - a coating consisting of a cellulose  
derivative, preferably cellulose acetate phthalate.

35 11.       Pharmaceutical formulation intended for local  
administration to a mucous membrane, characterized in  
that it essentially consists of a vaccine composition  
according to either Claim 3 or Claim 4 embedded in  
glycerol or a glycerol/glycerine-based mixture.

004030 6026360

12. Formulation according to Claim 11, characterized in that said vaccine composition consists of a freeze-dried mixture of immunosomes, onto which a gp120/160 protein is anchored, with trehalose.

004020" 2032E 360

## ABSTRACT

Use of HIV-1 gp120 and gp160 proteins which have been modified in the V3 loop for preparing vaccine compositions and formulations containing them which induce a systemic and mucosal immunity.

Use of a recombinant HIV-1 Env protein, in which the V3 loop is partially or completely deleted, for preparing a vaccine composition which is capable of inducing an immunity which is at the same time humoral, cellular and mucosal with respect to HIV-1.

The vaccine composition comprises:

- a recombinant Env protein as defined above,
- optionally at least one compound selected from the group consisting of: (1) the vaccination adjuvants selected from the group consisting of derivatives comprising divalent or trivalent ions: aluminium hydroxide or calcium phosphate, and muramylpeptide derivatives and (2) liposomes and
- optionally at least one pharmaceutically acceptable vehicle.

004080" 9082550